A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance
Source : https://pubmed.ncbi.nlm.nih.gov/38694500/
The emergence of resistance to prostate cancer (PCa) treatment, particularly to androgen deprivation therapy (ADT), has posed a significant challenge in the field of PCa management. Among the therapeutic options...
Addressing SIPS in PCa treatment requires balancing the benefits of senescent cell growth arrest with their negative effects on neighboring cells, necessitating innovative strategies to improve treatment outcomes.
Outcomes of ablative therapy and radical treatment for prostate cancer: a systematic review and meta-analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38446906/
Biochemical recurrence and urinary continence outcomes of ablative therapy and radical treatment were similar. Ablative therapy appears to have a high rate of sexual potency.
A systematic review and meta-analysis comparing ablative therapy with radical treatment for prostate cancer showed similar biochemical recurrence and urinary continence rates, but ablative therapy had higher sexual potency.
Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access
Source : https://pubmed.ncbi.nlm.nih.gov/38781539/
Genetic testing and molecular imaging have great promise in the accurate diagnosis and treatment of #prostate #cancer, but only if they can be developed and implemented to achieve equitable benefit...
In prostate cancer, genetic testing and molecular imaging guide prognosis and therapy, crucial for high-risk and metastatic cases. We address the rationale, potential pitfalls, and the need for equitable application.
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Source : https://pubmed.ncbi.nlm.nih.gov/38913213/
The management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate...
Metastatic castrate-resistant prostate cancer (mCRPC) management has advanced with genomic insights and novel therapies. Focus is on survival and QoL, with ongoing need for biomarker-guided treatment strategies.
Prostate Cancer and the Mevalonate Pathway
Source : https://pubmed.ncbi.nlm.nih.gov/38396837/
Antineoplastic therapies for prostate cancer (PCa) have traditionally centered around the androgen receptor (AR) pathway, which has demonstrated a significant role in oncogenesis. Nevertheless, it is becoming progressively apparent that...
Integrating the dysregulation of the lipid metabolic pathway into prostate cancer management is crucial for overcoming resistance mechanisms, enhancing therapeutic strategies, and improving patient outcomes in prostate cancer treatment.